Petros Pharmaceuticals Grants 7.25M RSUs to Executives and Directors, Signaling Significant Potential Dilution
PTPI has more than doubled off its 52-week low of $0.002.
Summary
Petros Pharmaceuticals granted 7.25 million restricted stock units (RSUs) to its Chairman, President & CCO, and two directors, representing a significant potential dilution of over 17% of the company's market cap.
Key Events · Executive and Board Changes · PTPI
-
Significant RSU Grants Approved
The Board of Directors approved grants of an aggregate of 7,250,000 restricted stock units (RSUs) to key executives and directors, effective January 2, 2026.
-
Key Recipients Identified
Recipients include Chairman Joshua Silverman (4,375,000 RSUs), President and Chief Commercial Officer Fady Boctor (500,000 RSUs), and Directors Bruce Bernstein (1,875,000 RSUs) and Wayne Walker (500,000 RSUs).
-
Immediate and Future Vesting
50% of each RSU grant vested immediately on the grant date, with the remaining 50% scheduled to vest on the six-month anniversary, contingent on continued service.
-
Substantial Potential Dilution
These RSU grants, valued at approximately $58,000 based on the current stock price, represent a potential dilution of about 17.11% of the company's current market capitalization, which is significant for a micro-cap company.
Analysis · PTPI · Life Sciences
Petros Pharmaceuticals, a micro-cap company, has approved substantial RSU grants to its Chairman, President & CCO, and two directors. While these are compensatory, the aggregate 7.25 million RSUs represent a significant potential dilution of approximately 17.11% of the company's current market capitalization. This level of dilution can materially impact per-share value for existing shareholders, especially for a company with such a small market cap. Investors should monitor the impact of these grants on the company's share structure and future stock performance.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1615 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTPI was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $339K. The 52-week trading range was $0.00 to $406.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.